T1	intervention 72 82	exemestane
T2	eligibility 528 751	postmenopausal women from five centres who were eligible to participate in MAP.3, not osteoporotic, not receiving drugs for bone-related disorders, with baseline lumbar spine, total hip, and femoral neck T-scores above -2·0
T3	outcome-Measure 821 885	total volumetric bone mineral density (BMD) at the distal radius
T4	No-of-participants 1301 1304	351
T5	intervention-participants 1312 1315	176
T6	control-participants 1334 1337	175
T7	control 1344 1351	placebo
T8	average-age 1364 1374	61·3 years
T9	No-of-participants 1486 1489	242
T10	intervention-participants 1528 1531	124
T11	control-participants 1550 1553	118
T12	outcome 1600 1664	mean percent change in total volumetric BMD at the distal radius
T13	intervention-value 1669 1674	-6·1%
T14	control-value 1725 1730	-1·8%
T15	outcome 2050 2118	mean percent change in total volumetric BMD from baseline to 2 years
T16	intervention-value 2123 2128	-5·0%
T17	control-value 2179 2184	-1·3%
T18	outcome 2276 2317	mean percent change in cortical thickness
T19	intervention-value 2322 2327	-7·9%
T20	control-value 2365 2370	-1·1%
T21	outcome 2398 2418	at the distal radius
T22	intervention-value 2473 2478	-7·6%
T23	control-value 2516 2521	-0·7%
T24	outcome 2549 2568	at the distal tibia
T25	outcome 2613 2633	Decline in areal BMD
T26	outcome 2749 2768	at the lumbar spine
T27	intervention-value 2770 2775	-2·4%
T28	control-value 2812 2817	-0·5%
T29	outcome 2891 2900	total hip
T30	intervention-value 2902 2907	-1·8%
T31	control-value 2937 2942	-0·6%
T32	outcome 3013 3025	femoral neck
T33	intervention-value 3027 3032	-2·4%
T34	control-value 3062 3067	-0·8%
